Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study.

ABSTRACT:

Purpose

To investigate the clinical impact of three available antivirals for early COVID-19 treatment in a large real-life cohort.

Methods

Between January and October 2022 all outpatients tested positive for SARS-CoV-2 referring to IRCCS S. Orsola hospital treated with an early antiviral therapy were enrolled. A comparison between patients treated with nirmatrelvir/ritonavir (NTV/r), molnupiravir (MPV) and remdesivir (RDV) was conducted in term of indications and outcome. To account for differences between treatment groups a propensity score analysis was performed. After estimating the weights, we fitted a survey-weighted Cox regression model with inverse-probability weighting with hospital admission/death versus clinical recovery as the primary outcome.

Results

Overa

SUBMITTER: Rinaldi M 

PROVIDER: S-EPMC10546723 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature